Abstract: The present invention relates to a process for manufacturing (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below and pharmaceutically acceptable salts thereof The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to a new intermediate of said process.
Type:
Application
Filed:
July 26, 2021
Publication date:
June 16, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Martin Juhl, Lisbet Kværnø, Mikkel Fog Jacobsen
Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
June 14, 2022
Assignee:
H. Lundbeck A/S
Inventors:
John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PH F) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Type:
Application
Filed:
August 11, 2021
Publication date:
June 9, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Jan Torleif Pedersen, Kristian Kjaergaard, Lars Østergaard Pedersen, Ayodeji Abdur-Rasheed Asuni, Nina Helen Rosenqvist, Justus Claus Alfred Daechsel, Karsten Juhl, Lena Tagmose, Mauro Marigo, Thomas Jensen, Søren Christensen, Laurent David, Christiane Volbracht, Lone Helboe
Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
June 7, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Maria-Cristina Loomis, Leon Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
Abstract: The present invention relates to a process for synthesis of 4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3-ol abbreviated THIP, having the INN name gaboxadol, starting from pyrrolidin-2-one. The process comprises a new direct process to obtain the intermediate dimethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate or the intermediate diethyl 5-hydroxy-3,6-dihydropyridine-1,4(2H)-dicarboxylate.
Type:
Grant
Filed:
March 24, 2020
Date of Patent:
May 17, 2022
Assignee:
H. Lundbeck A/S
Inventors:
Carla De Faveri, Florian Anton Martin Huber
Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
May 14, 2019
Date of Patent:
May 17, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.
Type:
Grant
Filed:
April 18, 2019
Date of Patent:
May 10, 2022
Assignees:
H. LUNDBECK A/S, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian R. Kovacevich, John Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez
Abstract: The present invention relates to a mouse antibody denoted m2E6, chimeric ch2E6, as well as to 3 humanized forms (2E6-HLD1, 2E6-HLD2 and 2E6-HLD3) and affinity matured forms of HLD1: 7A10, 5A1, 9D7, 9G11, 7C4, L3, 8D9, 9C12 or 6B6 to create higher affinity antibodies.
Abstract: Provided herein are pharmaceutical formulations comprising a monoacylglycerol lipase (MAGL) inhibitor, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
March 15, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Nicole S. White, Joel P. Zingerman, Hibreniguss Terefe, Isaac Ghebre-Sellassie
Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.
Type:
Grant
Filed:
January 8, 2019
Date of Patent:
February 22, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Maria-Cristina Loomis, Leon F. Garcia-Martinez, Benjamin H. Dutzar, Daniel S. Allison, Katherine Lee Hendrix, Ethan W. Ojala, Pei Fan, Jeffrey T. L. Smith, John A. Latham, Charlie Karasek, Jenny Mulligan, Michelle Scalley-Kim, Erica Stewart, Vanessa Lisbeth Rubin, Jens J. Billgren
Abstract: The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine in the form of 2a and 2b, wherein X—is a counter ion, or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising prodrugs, or pharmaceutically acceptable salts thereof, of the invention.
Abstract: The present invention relates to new solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid with the formula (Id) below. The compound of formula (Id) is a prodrug of a catecholamine for use in treatment of neurodegenerative diseases and disorders such as Parkinson's Disease.
Type:
Application
Filed:
August 3, 2021
Publication date:
January 27, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl, Heidi Lopez de Diego, Karin Fredholt, Frans Dennis Therkelsen, Tobias Gylling Frihed, Mikkel Fogh Jacobsen
Abstract: The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6 a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4?,5?:5,6]benzo[1,2-g]quinoline with formula (Ib) below, (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol with formula (I) below and salts thereof. Both compounds are for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediate compounds of said process.
Type:
Application
Filed:
October 7, 2021
Publication date:
January 27, 2022
Applicant:
H. Lundbeck A/S
Inventors:
Mikkel Fog Jacobsen, Martin Juhl, Frans Dennis Therkelsen, Kåre Søndergaard, Tobias Gylling Frihed
Abstract: Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
Type:
Grant
Filed:
October 29, 2018
Date of Patent:
January 18, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Danielle Marie Mitchell, Leon F. Garcia-Martinez, Patricia Dianne McNeill, Ethan Wayne Ojala, Mehmet Inan, John Latham
Abstract: Methods for producing heterologous multi-subunit proteins in transformed cells are disclosed. In particular, the present disclosure provides improved methods of producing multi-subunit proteins, including antibodies and other multi-subunit proteins, which may or may not be secreted, with a higher yield and decreased production of undesired side-products. In exemplary embodiments, the transformed cells are a yeast, e.g., methylotrophic yeast such as Pichia pastoris.
Type:
Grant
Filed:
May 8, 2012
Date of Patent:
January 4, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Patricia Dianne McNeill, Leon F. Garcia-Martinez, Nicole Janson, Gary Lesnicki, Pei Qi, John A. Latham
Abstract: Provided herein are piperazine carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
January 10, 2020
Date of Patent:
January 4, 2022
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Daniel J. Buzard, Michael B. Shaghafi
Abstract: The present invention relates to a new process for manufacturing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4?,5?:5,6]benzo[1,2-g]quinoline with formula (Ib) below, (4aR,10aR)-1-Propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol with formula (I) below and salts thereof. Both compounds are for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's Disease. The invention also relates to new intermediate compounds of said process.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
November 9, 2021
Assignee:
H. Lundbeck A/S
Inventors:
Mikkel Fog Jacobsen, Martin Juhl, Frans Dennis Therkelsen, Kåre Søndergaard, Tobias Gylling Frihed
Abstract: Provided herein are compounds of the formula: and compositions comprising the same, which are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
August 28, 2018
Date of Patent:
November 2, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Olivia D. Weber, Daniel J. Buzard, Michael B. Shaghafi
Abstract: Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
Type:
Grant
Filed:
May 22, 2018
Date of Patent:
October 19, 2021
Assignee:
H. LUNDBECK A/S
Inventors:
Cheryl A. Grice, Olivia D. Weber, Daniel J. Buzard, Michael B. Shaghafi, John J. M. Wiener, Justin S. Cisar, Katharine K. Duncan